Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4-chloro-N'-[(1E)-(3,5-dibromo-2,4-dihydroxyphenyl)methylidene]benzohydrazide is an experimental small molecule belonging to the class of organic compounds known as 4-halobenzoic acids and derivatives. It features a benzohydrazide backbone substituted with a chloro group and a dibromodihydroxyphenyl moiety via a hydrazone linkage. The compound has been studied for its potential biological activity and is reported to act as an inhibitor of the bacterial enzyme 3-hydroxyacyl-[acyl-carrier-protein] dehydratase FabZ. This enzyme plays a key role in unsaturated fatty acid biosynthesis in bacteria[1][2][6]. The compound's mechanism suggests possible antibacterial properties by targeting lipid biosynthesis pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4-chloro-N'-[(1E)-(3,5-dibromo-2,4-dihydroxyphenyl)methylidene]benzohydrazide.